Trastuzumab in the treatment of non-small cell lung cancer Journal Article
| Authors: | Azzoli, C. G.; Krug, L. M.; Miller, V. A.; Kris, M. G.; Mass, R. |
| Article Title: | Trastuzumab in the treatment of non-small cell lung cancer |
| Abstract: | Trastuzumab is a humanized monoclonal antibody that binds to human epidermal growth factor-2 (HER2) and is approved by the US Food and Drug Administration for the treatment of advanced breast cancer that overexpresses HER2/neu protein. Preclinical data suggests a role for trastuzumab in the treatment of non-small cell lung cancer (NSCLC). HER2 protein is overexpressed in 20% to 66% of resected NSCLC tumors, and has been shown to predict poor patient outcome in multiple series. Experiments with NSCLC cell lines show that HER2 overexpression increases chemoresistance, invasiveness, and metastatic potential of the cells. In mouse xenograft experiments, trastuzumab halts tumor growth and is synergistic with cytotoxic chemotherapy. Ongoing phase II trials are showing that trastuzumab can be added to standard chemotherapy in the treatment of patients with advanced NSCLC without additional toxicity, and with promising efficacy. Whether trastuzumab will show a clear benefit for patients with NSCLC, either alone or in combination with established chemotherapy, remains to be proven in phase III testing. Copyright 2002, Elsevier Science (USA). All rights reserved. |
| Keywords: | epidermal growth factor; clinical trial; review; cisplatin; cancer combination chemotherapy; drug efficacy; nonhuman; antineoplastic agents; gemcitabine; paclitaxel; mouse; gene overexpression; carboplatin; phase 2 clinical trial; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; animal experiment; animal model; cancer cell culture; drug resistance, neoplasm; cancer model; cancer resistance; docetaxel; monoclonal antibody; cancer invasion; antibodies, monoclonal; neoplasm metastasis; receptor, erbb-2; neoplasm invasiveness; metastasis potential; up-regulation; tumor growth; toxicity; trastuzumab; clinical trials; oncogene neu; humans; prognosis; human; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 29 |
| Issue: | 1 Suppl.4 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2002-02-01 |
| Start Page: | 59 |
| End Page: | 65 |
| Language: | English |
| PUBMED: | 11894015 |
| PROVIDER: | scopus |
| DOI: | 10.1053/sonc.2002.31526 |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work